Physician profile
Douglas M Leppink
NPI 1306901368
$1,218.75
in general payments reported to CMS, 2019-2025
12 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $91.26 · 2021: $126 · 2022: $84.08 · 2023: $167 · 2024: $281 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $561.83 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $124.61 | 2019-2025 | |
| Abbvie INC. | $116.01 | 2023-2024 | |
| Integra Lifesciences Corporation | $114.91 | 2023-2024 | Integra, Omnigraft, Surgimend |
| Allergan, INC. | $70.31 | 2019-2020 | |
| Motiva USA, LLC | $63.05 | 2025 | |
| Tela Bio, INC. | $36.33 | 2022 | |
| Revance Therapeutics, INC. | $31.42 | 2025 | Daxxify |
| Tepha INC | $27.57 | 2019 | |
| Heron Therapeutics, INC. | $27.02 | 2024 | Zynrelef |
| Kls-Martin L.P. | $26.17 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $19.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Leppink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.